scholarly journals Adjuvant Treatment Approach in Primary Apocrine Adenocarcinoma Presenting With Axillary Mass: A Case Report

2020 ◽  
Author(s):  
Gulcan Bulut ◽  
Sukran Senyurek ◽  
Remziye Eren
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Female Patient ◽  
Hormone Receptor ◽  
Sweat Gland ◽  
Adjuvant Radiation ◽  
Apocrine Carcinoma ◽  
Occult Breast Cancer ◽  
Case Presentation ◽  
Apocrine Sweat Gland

Abstract Background: Primary apocrine sweat gland adenocarcinoma is a very rare tumor. Apocrine carcinoma is a high incidence of local recurrence and lymph node metastasis. When the location of the tumor is axilla, it should be differentiated from occult breast cancer. Surgery is the first step in primary apocrine cancer treatment. However, there is no clear consensus about adjuvant part of treatment. In this case, we presented a 60-year old female patient with primary apocrine sweat gland carcinoma of the axilla. To our knowledge, this is the first case in the literature to use combined adjuvant radiation therapy and anti-estrogen therapy.Case presentation: A 60-year old female patient presented with a slowly growing mass in the right axilla. The patient was examined by a surgeon and there was suspected to be metastasis from breast cancer diagnosed in September 2017. Axillary localized apocrine carcinoma was differentiated from occult breast cancer by pathological findings. For this reason, the patient was operated only an axillary dissection operation. Operated patient with axillary apocrine carcinoma was treated with radiotherapy. As a result of pathological evaluation of the tumor, tamoxifen was added to the treatment when the hormone receptor was positive.Conclusions: The pathological features must be evaluated in detail for targeted treatment, which should be ap-plied with a multidisciplinary approach. Based on this case presentation and literature, adjuvant radiotherapy can be recommended to reduce the risk of local recurrence and hormone-therapy to reduce distant recurrence in patients with hormone-receptor positive primary apocrine carcinoma.

A Case of Primary Apocrine Adenocarcinoma Presenting With Axillary Mass

2021 ◽  
Author(s):  
Gulcan Bulut ◽  
Sukran Senyurek Celikaslan ◽  
Remziye Eren
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Surgery ◽  
Apocrine Carcinoma ◽  
Rare Tumour ◽  
Occult Breast Cancer ◽  
Pathological Evaluation ◽  
Apocrine Adenocarcinoma ◽  
Apocrine Sweat Gland ◽  
Axillary Mass

Abstract Introduction: Primary apocrine sweat gland adenocarcinoma is a very rare tumour. Apocrin carcinoma is a high incicence of local recurrence and lymph node metastasis. When the location of the tumor is axilla, it should be differentiated from occult breast cancer. Surgery is the first step in primary apocrine cancer treatment. However, there is no clear consensus about adjuvant part of treatment.Methods: The case with axillary apocrin carcinoma was presentated diagnosis, differential diagnosis and treatment approach.Result : Axillary localized apocrine carcinoma was differentiated from occult breast cancer by pathological findings. For this reason, the patient was operated only an axillary dissection operation. Operated patient with axillary apocrine carcinoma was treated with radiotherapy. As a result of pathological evaluation of the tumor, tamoxifen was added to the treatment when the hormone receptor was positive.Conclusions: The patient with apocrine carcinoma was treated with sequential radiotherapy and tamoxifen, and disease-free follow-up to this day

scholarly journals Systemic Therapy in Local Recurrence of Breast Cancer, Report of a case and Decision Making in MDT Meeting

2019 ◽  
pp. 120-123
Author(s):  
Melina Deban ◽  
Rami Younan ◽  
Danielle Charpentier ◽  
Louise Yelle ◽  
Danh Tran-Thanh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Local Recurrence ◽  
Systemic Therapy ◽  
Hormone Receptor ◽  
Tertiary Care ◽  
Neoadjuvant Treatment ◽  
Radical Mastectomy ◽  
R0 Resection ◽  
Hormone Receptor Positive ◽  
Her 2

Background: Locoregional recurrence of breast cancer has significantly decreased over the last decades, particularly due to effective systemic therapy. While there is little controversy regarding local management of locoregional recurrences, in light of previous systemic treatment, additional chemotherapy regimens and their benefit to the patient are still subject to debate in tumors boards.Case Presentation: A 45-year-old woman was referred to our tertiary care center with a local recurrence of breast cancer 9 years after modified radical mastectomy for a ypT2N2a invasive ductal carcinoma. She received neoadjuvant treatment consisting of FEC-D (5-FU-epirubicin-cyclophosphamide, followed by docetaxel) for hormone receptor positive, HER-2-neu negative cancer in 2009, as well as adjuvant radiotherapy and tamoxifen for 9 years. After R0 resection of the hormone receptor positive, HER-2-neu negative recurrence in 2019, adjuvant therapy with ovarian suppression and an aromatase inhibitor was undertaken. A multigene assay identified a recurrence score at 37 and benefit from chemotherapy > 15%.Question: What would the ideal chemotherapy regimen consist of for this patient with an R0 resection of late recurrence of breast cancer?Conclusion: After reviewing history, imaging and pathology, members of the multidisciplinary team recommended treatment with Taxotere and cyclophosphamide (TC) x 4 for our patient.

scholarly journals Management of Adenoid Cystic Carcinoma of the Breast: A Single-Institution Study

2021 ◽  
Vol 11 ◽  
Author(s):  
Wenxiang Zhang ◽  
Yi Fang ◽  
Zhihui Zhang ◽  
Jing Wang
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Local Recurrence ◽  
Adenoid Cystic Carcinoma ◽  
Distant Metastasis ◽  
Hormone Receptor ◽  
Clinical Presentation ◽  
Hormone Receptor Positive ◽  
Adenoid Cystic

ObjectiveThe purpose of our study was to analyze the clinicopathologic features and surgical and oncological outcomes of adenoid cystic carcinoma (ACC) of the breast and to provide the basis for a clinical therapeutic schedule.MethodsA total of 14 patients with primary breast adenoid cystic carcinoma treated at Cancer Hospital of the Chinese Academy of Medical Sciences from January 2000 to December 2017 were included. Data on clinical presentation, treatment strategy, and outcome, as well as the pathological features of ACC, were reviewed and analyzed.ResultsFourteen patients were diagnosed with ACC of the breast, out of 23205 total patients treated for breast cancer (0.06%). All but three patients were postmenopausal, with a median age at diagnosis of 60.5 years (range, 39–73 years). The most common clinical presentation was a palpable mass (85.7%), and the imaging characteristics of all patients on color Doppler ultrasound and mammography were nonspecific. Six patients (42.9%) were suspected of having ACC by fine-needle aspiration cytology (FNAC) and were confirmed by postoperative histology and immunohistochemistry. All 14 patients underwent surgery, and no patient had a positive lymph node status. Median tumor size was 1.75 cm (range, 1–3 cm). Eight/14 (57.1%) patients were hormone receptor negative (HR−) and HER-2/neu (−) (HER2−). The remaining patients were hormone receptor positive (HR+). There was no significant difference in clinicopathological characteristics between the HR+ group and the HR- group (P>0.05). The mean follow-up period was 57 months. Local recurrence occurred in 14.3% of patients, 1.7% of patients had distant metastasis, all patients with local recurrence or distant metastasis were in the HR (-) group, and all patients were alive at the last follow-up.ConclusionACC of the breast cannot be simply summarized as triple-negative breast cancer because it also includes a small number of hormone receptor-positive breast cancers. Establishing a preoperative diagnosis is difficult on the basis of clinical imaging examination, FNAC may be useful tool in the diagnosis. the final diagnosis can only be assessed based on the results of the histopathological and immunohistochemical examination. Breast-conserving surgery may be an alternative treatment strategy, and axillary lymph node dissection or sentinel node biopsy may not be necessary in some cases.

Breast cancer: First results of an institutional cancer registry 2007-2011 in Colombia.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e12571-e12571 ◽  
Author(s):  
Andres Yepes ◽  
Luis Gonzalez ◽  
Isabel Cristina Durango ◽  
Beatriz Pineda ◽  
Juan D. Figueroa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Invasive Ductal Carcinoma ◽  
Cancer Registry ◽  
Hormone Receptor ◽  
Ductal Carcinoma ◽  
Stage I ◽  
Adjuvant Radiation ◽  
Luminal A ◽  
Patient Profile

e12571 Background: The aim of this retrospective study was to describe the clinical characteristics of patients with breast cancer (BC) treated at the Oncology Unit of the Hospital Pablo Tobon Uribe in Medellin, Colombia, an institution's 10-year experience. Methods: All cases were Identified from our institution's cancer registry from 2007-2011. Results: During the study period 1224 BC were cases identified. Men: 12 (1%). Median age at diagnosis was 56 years (range 23-88). Stage at diagnosis was stage 0 (6.1%), stage I (30%), stage IIA (24.5%), stage IIB (10.8%), stage IIIA (6.8%), stage IIIB ( 6.1%), stage IIIC (9.5%), stage IV (3.4%) and unknown (2.8%). Primary right breast (50.2%). Most common histology was invasive ductal carcinoma (71%) and histologic grade 2 (34.6%). Estrogen and progesterone receptor status assessed at diagnosis was positive in 74,7% and 69% of cases tested respectively. HER2/neu status was positive in 14.2% (with hormone receptor positive 8,1% and hormone receptor negative 6.1%). Triple-negative BC 12.2%. Median tumor size was 2.3 cm (range 0.4-14.0 cm). Procedure performed was mastectomy in 59% and lumpectomy in 35%. Nodal staging was performed by axillary dissection (AD) (81%) and sentinel node biopsy (SN) alone (19%). Neoadjuvant chemotherapy was given to 39%, adjuvant chemotherapy to 69%, adjuvant hormonal therapy to 62% and adjuvant radiation therapy was used in 40,6%. The preferred adjuvant regimens was AC (doxorubicin / cyclophosphamide) followed by weekly paclitaxel in 51%. The average time from diagnosis to entry into consultation with specialist breast surgery 12 days. Time from diagnosis and staging complete and the beginning of the treatment: 16 days. Conclusions: The patient profile inquiry to our hospital with breast cancer is a woman of 56 years, with commitment right breast, invasive ductal carcinoma, grade 2, luminal A (estrogen receptor positive and / or progesterone receptor positive, HER2 negative), stage I and most commonly treated with mastectomy and chemotherapy with AC and paclitaxel.

Sign in / Sign up

Export Citation Format

Share Document